| 26.2.13
|
CVA Reading 1, p.33, pl. 21, no.9a-b; Villing et al 2013-2015 (ORC) GE.076 Phase 3;
|
|
| 26.2.14
|
CVA Reading 1, p.33. pl. 21, no.10a-b; Villing et al 2013-2015 (ORC) GG.380;
|
|
| 26.2.16
|
CVA Reading 1, p.33, pl. 21, no.12a-b; Villing et al 2013-2015 (ORC) GE.256 Phase 3;
|
|
| 26.2.7
|
CVA Reading 1, p.33, pl. 21, no.3a-b; Villing et al 2013-2015 (ORC) GG.460;
|
|
| 26.2.8
|
CVA Reading 1, p.33, pl. 21, no.4; Villing et al 2013-2015 (ORC) GO.118
|
|
| 26.2.9
|
CVA Reading 1, p.33, pl. 21, no.5a-b; Villing et al 2013-2015 (ORC) GG.085;
|
|